Protagonist Therapeutics (PTGX)
(Real Time Quote from BATS)
$28.48 USD
0.00 (0.00%)
Updated Mar 28, 2024 10:32 AM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Brokerage Reports
Protagonist Therapeutics, Inc. [PTGX]
Reports for Purchase
Showing records 1 - 20 ( 47 total )
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Another Blockbuster Partnership for Protagonist as Takeda Inks Deal for Rusfertide; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
JNJ Raise the Bar for JNJ-2113 at Analyst Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
JNJ-2113 Stands Apart and Rusfertide Plows Ahead Without Missing a Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Update: Assets Gain Recognition as Balance Sheet Gains Strength; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
JNJ-2113 Looks to Be a Winner From Our Vantage Point
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EHA Presentation Showcases Efficacy of Rusfertide; Additional Extension Study Announced; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent Data Increase Our Confidence in Multiple Assets; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Conversation With Protagonist Therapeutics; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Positive Data for Rusfertide Continues to Mount; Raise PT to $38; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Protagonist Stands to Gain as FRONTIER Delivers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
It Might Take a Little Longer to VERIFY Rusfertide in PV Though We Remain Bullish; PT Down to $33; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rusfertide Remains the Focus as PN-943 To Be Advanced With a Partner; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
When Less is More as PN-943 Shows a Strong Signal at Lower Dose; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Has Second Thoughts on Breakthrough Designation for Rusfertide; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Protagonists Diverse Pipeline Moving Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Update From ASH: Rusfertide Continues to Dramatically Reduce TP Need, Now in High HCT Patients Too; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Janssen and Protagonist Zero in on PN-235 for All IL-23 Indications Going Forward; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Another Win for Rusfertide, This Time in Hereditary Hemochromatosis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Protagonist Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Janssen Opts-Out of PTG-200 in Favor of 2nd Gen Assets as Value Proposition Remains Unchanged; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D